Joshua Brody, MD, on Lymphoid Malignancies: Immunotherapy Update

2016 ASH Annual Meeting & Exposition

Joshua Brody, MD, of the Icahn School of Medicine at Mount Sinai, summarizes important data on passive and active immunotherapy (Abstracts 1213, 1214, 1215, 1216, 1217, 1218).

Aug

Today In Oncology

FDA Approves Lenvatinib for Unresectable Hepatocellular Carcinoma

Issues in Doctor-Patient Discussions on Potential Harms of Lung Cancer Screening

VB4-845 Granted Fast Track Designation by FDA for Treatment of Non–Muscle Invasive Bladder Cancer

Basal Cell Carcinoma and Risk for Development of Other Cancers

Broad-Based Genomic Sequencing in Advanced NSCLC in the Community Oncology Setting

;